Serotype replacement in disease after pneumococcal vaccinationArchived
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.
Mumps Complications and Effects of Mumps Vaccination, England and Wales, 2002–2006Archived
The authors analyzed data from hospital admissions and enhanced mumps surveillance to assess mumps complications during the largest mumps outbreak in England and Wales, 2004–2005, and their association with mumps vaccination. When compared with non-outbreak periods, the outbreak was associated with a clear increase in hospitalized patients with orchitis, meningitis and pancreatitis. Routine mumps surveillance and hospital data showed that 6.1% of mumps patients were hospitalized, 4.4% had orchitis, 0.35% meningitis and 0.33% pancreatitis.
Two evaluations of the response to the 2009 Pandemic in Spain: Surveillance and Vaccines and antiviralsArchived
Two official evaluations have been made by the national Ministry of Health of Spain of their country’s response to the 2009 influenza pandemic. The reviews focused on two particular topics - Surveillance and Vaccines and Antivirals.
Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in childrenArchived
The study compares the incidence and serotype distribution of invasive pneumococcal disease (IPD) for pneumococcal meningitis and non-meningitis IPD in children from 2007 to 2010 with reference to the pre-vaccination period from 1997 to 2001 in Germany.
WHO recommendations for influenza virus vaccine composition for the 2018 southern hemisphere influenza season
The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.